In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen/Abgenix: All About a Drug

Executive Summary

Amgen is using its cash to buy near-term products-the fundamental reason behind its purchase of Abgenix. Indeed, the irony to this transaction is that while the promise of genomics generated the money Abgenix needed to stay alive, the product that ultimately made Abgenix's fortune is an antibody to an entirely pre-genomic target, the fourth in its target class to make it to market, and the second antibody to do so.
Advertisement

Related Content

Can Amgen Find a New Engine?
Share the Wealth? No Thanks
The Large Molecule Future
Deal Statistics Quarterly, Q4 2005
AstraZeneca Joins the In-Licensing Game
Biosimilars: The Time Has Come
CAT Gains from AZ Antibody Drive
Pfizer Opts for Access Over Exclusivity in Antibodies
Who's Got Game in Antibody Development?
What's Driving Amgen?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel